Related Experiment Videos
Risk profile of SSrIs in elderly depressive patients with co-morbid physical illness
I Kurzthaler1, A Hotter, C Miller
1Department of Biological Psychiatry, University of Innsbruck, Austria. ilsemarie.kurzthaler@uibk.ac.at
Pharmacopsychiatry
|July 4, 2001
Summary
Selective serotonin reuptake inhibitors (SSRIs) are effective and safe for elderly patients with depression and physical illnesses. While side effects are more common, they are generally manageable, indicating a favorable risk profile.
Area of Science:
- Geriatric Psychiatry
- Pharmacology
- Internal Medicine
Background:
- Elderly patients with depression often have co-morbid physical illnesses, a factor frequently excluded in treatment studies.
- Somatic co-morbidity is highly prevalent and significant in geriatric psychiatry.
Purpose of the Study:
- To evaluate the safety and efficacy of Selective Serotonin Reuptake Inhibitors (SSRIs) in elderly depressive patients with co-morbid physical conditions.
- To assess the adverse event profile of SSRIs in this specific patient population.
Main Methods:
- A prospective post-marketing surveillance study involving 40 elderly depressive inpatients with stable physical illnesses.
- Patients received SSRI monotherapy (paroxetine, citalopram, fluoxetine, or sertraline) for four weeks.
- Assessments included psychiatric and medical history, psychopathology ratings (HAMD), and adverse events (UKU, HAS).
Main Results:
- SSRIs demonstrated effectiveness in treating depression in elderly patients with co-morbid physical illnesses.
- Adverse effects were observed but were generally tolerable and considered manageable.
- The incidence of SSRI-induced akathisia was specifically monitored.
Conclusions:
- SSRIs are a viable and reasonably safe treatment option for elderly individuals suffering from depression alongside physical health issues.
- The risk-benefit profile of SSRIs in this population is considered favorable despite a higher incidence of side effects compared to younger, healthier patients.